SOLRIAMFETOL HYDROCHLORIDE Drug Patent Profile
When do Solriamfetol Hydrochloride patents expire, and what generic alternatives are available?
Solriamfetol Hydrochloride is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, and Hikma. and is included in three NDAs.
The generic ingredient in SOLRIAMFETOL HYDROCHLORIDE is solriamfetol hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the solriamfetol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Solriamfetol Hydrochloride
A generic version of SOLRIAMFETOL HYDROCHLORIDE was approved as solriamfetol hydrochloride by ALKEM LABS LTD on June 17th, 2026.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SOLRIAMFETOL HYDROCHLORIDE?
- What are the global sales for SOLRIAMFETOL HYDROCHLORIDE?
- What is Average Wholesale Price for SOLRIAMFETOL HYDROCHLORIDE?
Summary for SOLRIAMFETOL HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 9 |
| Clinical Trials: | 20 |
| Patent Applications: | 76 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SOLRIAMFETOL HYDROCHLORIDE |
| DailyMed Link: | SOLRIAMFETOL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for SOLRIAMFETOL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital, Montpellier | PHASE2 |
| Duke University | PHASE2 |
| Axsome Therapeutics, Inc. | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for SOLRIAMFETOL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for SOLRIAMFETOL HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SUNOSI | Tablets | solriamfetol hydrochloride | 75 mg and 150 mg | 211230 | 6 | 2023-06-20 |
US Patents and Regulatory Information for SOLRIAMFETOL HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Labs Ltd | SOLRIAMFETOL HYDROCHLORIDE | solriamfetol hydrochloride | TABLET;ORAL | 218722-001 | Jun 17, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Aurobindo Pharma Ltd | SOLRIAMFETOL HYDROCHLORIDE | solriamfetol hydrochloride | TABLET;ORAL | 218725-002 | Oct 6, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Alkem Labs Ltd | SOLRIAMFETOL HYDROCHLORIDE | solriamfetol hydrochloride | TABLET;ORAL | 218722-002 | Jun 17, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

